http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 13 Nov 2025 10:43:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Shaperon+Attends+7th+Inflammasome+Therapeutics+Summit+in+Boston%3B+CEO+Dr.+Seungyong+Seong+Delivers+Keynote+Presentation+on+GPCR19-Targeted+Drug+Development/25604388.html <p> - Highlights clinical progress in GPCR19-targeted inflammasome modulation for atopic dermatitis and alopecia. </p><p> - Showcases AI-driven pipeline momentum and partnering path toward global commercialization </p> <p> SEOUL, South Korea--(BUSINESS WIRE)-- Shaperon Inc. (KOSDAQ: 378800) a clinical-stage biotechnology company specializing in GPCR19-targeted immunomodulatory drugs, announced that it attended the 7th Inflammasome Therapeutics Summit held in Boston, Massachusetts, from November 4-6, 2025. During the event, CEO Dr. Seungyong Seong delivered a keynote presentation highlighting the company’s latest clinical and preclinical achievements in the development of inflammasome-modulating therapies for atopic dermatitis and alopecia areata. </p><p> The Inflammasome Therapeutics Summit is a leading global conference dedicated to http://www.streetinsider.com/Press+Releases/Shaperon+Attends+7th+Inflammasome+Therapeutics+Summit+in+Boston%3B+CEO+Dr.+Seungyong+Seong+Delivers+Keynote+Presentation+on+GPCR19-Targeted+Drug+Development/25604388.html Thu, 13 Nov 2025 10:43:00 -0500 378800 O.10926566 http://www.streetinsider.com/Press+Releases/Shaperon+Attends+7th+Inflammasome+Therapeutics+Summit+in+Boston%3B+CEO+Dr.+Seungyong+Seong+Delivers+Keynote+Presentation+on+GPCR19-Targeted+Drug+Development/25604388.html <p> - Highlights clinical progress in GPCR19-targeted inflammasome modulation for atopic dermatitis and alopecia. </p><p> - Showcases AI-driven pipeline momentum and partnering path toward global commercialization </p> <p> SEOUL, South Korea--(BUSINESS WIRE)-- Shaperon Inc. (KOSDAQ: 378800) a clinical-stage biotechnology company specializing in GPCR19-targeted immunomodulatory drugs, announced that it attended the 7th Inflammasome Therapeutics Summit held in Boston, Massachusetts, from November 4-6, 2025. During the event, CEO Dr. Seungyong Seong delivered a keynote presentation highlighting the company’s latest clinical and preclinical achievements in the development of inflammasome-modulating therapies for atopic dermatitis and alopecia areata. </p><p> The Inflammasome Therapeutics Summit is a leading global conference dedicated to http://www.streetinsider.com/Press+Releases/Shaperon+Attends+7th+Inflammasome+Therapeutics+Summit+in+Boston%3B+CEO+Dr.+Seungyong+Seong+Delivers+Keynote+Presentation+on+GPCR19-Targeted+Drug+Development/25604388.html Thu, 13 Nov 2025 10:43:00 -0500 378800 O.10926566 http://www.streetinsider.com/Business+Wire/Shaperon+Attends+7th+Inflammasome+Therapeutics+Summit+in+Boston%3B+CEO+Dr.+Seungyong+Seong+Delivers+Keynote+Presentation+on+GPCR19-Targeted+Drug+Development/25604388.html <p> - Highlights clinical progress in GPCR19-targeted inflammasome modulation for atopic dermatitis and alopecia. </p><p> - Showcases AI-driven pipeline momentum and partnering path toward global commercialization </p> <p> SEOUL, South Korea--(BUSINESS WIRE)-- Shaperon Inc. (KOSDAQ: 378800) a clinical-stage biotechnology company specializing in GPCR19-targeted immunomodulatory drugs, announced that it attended the 7th Inflammasome Therapeutics Summit held in Boston, Massachusetts, from November 4-6, 2025. During the event, CEO Dr. Seungyong Seong delivered a keynote presentation highlighting the company’s latest clinical and preclinical achievements in the development of inflammasome-modulating therapies for atopic dermatitis and alopecia areata. </p><p> The Inflammasome Therapeutics Summit is a leading global conference dedicated to http://www.streetinsider.com/Business+Wire/Shaperon+Attends+7th+Inflammasome+Therapeutics+Summit+in+Boston%3B+CEO+Dr.+Seungyong+Seong+Delivers+Keynote+Presentation+on+GPCR19-Targeted+Drug+Development/25604388.html Thu, 13 Nov 2025 10:43:00 -0500 378800 O.10926566 http://www.streetinsider.com/Business+Wire/Shaperon+Attends+7th+Inflammasome+Therapeutics+Summit+in+Boston%3B+CEO+Dr.+Seungyong+Seong+Delivers+Keynote+Presentation+on+GPCR19-Targeted+Drug+Development/25604388.html <p> - Highlights clinical progress in GPCR19-targeted inflammasome modulation for atopic dermatitis and alopecia. </p><p> - Showcases AI-driven pipeline momentum and partnering path toward global commercialization </p> <p> SEOUL, South Korea--(BUSINESS WIRE)-- Shaperon Inc. (KOSDAQ: 378800) a clinical-stage biotechnology company specializing in GPCR19-targeted immunomodulatory drugs, announced that it attended the 7th Inflammasome Therapeutics Summit held in Boston, Massachusetts, from November 4-6, 2025. During the event, CEO Dr. Seungyong Seong delivered a keynote presentation highlighting the company’s latest clinical and preclinical achievements in the development of inflammasome-modulating therapies for atopic dermatitis and alopecia areata. </p><p> The Inflammasome Therapeutics Summit is a leading global conference dedicated to http://www.streetinsider.com/Business+Wire/Shaperon+Attends+7th+Inflammasome+Therapeutics+Summit+in+Boston%3B+CEO+Dr.+Seungyong+Seong+Delivers+Keynote+Presentation+on+GPCR19-Targeted+Drug+Development/25604388.html Thu, 13 Nov 2025 10:43:00 -0500 378800 O.10926566 http://www.streetinsider.com/Press+Releases/Shaperon+and+Dong-A+ST+Sign+MOU+for+Nanobody-Based+New+Drug+Development/23342134.html <ul class="bwlistdisc"> <li> Shaperon and Dong-A ST aim to maximize synergy through collaboration between Shaperon's nanobody development platform technology and Dong-A ST's antibody commercialization technology. </li> <li> The joint development of triple nanobody antibodies for cancer treatment is set to accelerate, with the goal of achieving visible results within the year. </li> </ul> <p> CAMBRIDGE, Mass &amp; RESEARCH TRIANGLE PARK, N.C. &amp; SEOUL, South Korea--(BUSINESS WIRE)-- Hudson Therapeutics announced that Shaperon (KOSDAQ 378800, CEO Seung-Yong Seong), an innovative biopharmaceutical company specializing in immune therapeutics, has signed a Memorandum of Understanding (MOU) with Dong-A ST (KOSPI 170900, CEO Min-Young Kim) for the development of nanobody-based new drugs. </p><p http://www.streetinsider.com/Press+Releases/Shaperon+and+Dong-A+ST+Sign+MOU+for+Nanobody-Based+New+Drug+Development/23342134.html Mon, 10 Jun 2024 15:29:00 -0500 3788 378800 A.26689212 O.10926566 http://www.streetinsider.com/Press+Releases/Shaperon+and+Dong-A+ST+Sign+MOU+for+Nanobody-Based+New+Drug+Development/23342134.html <ul class="bwlistdisc"> <li> Shaperon and Dong-A ST aim to maximize synergy through collaboration between Shaperon's nanobody development platform technology and Dong-A ST's antibody commercialization technology. </li> <li> The joint development of triple nanobody antibodies for cancer treatment is set to accelerate, with the goal of achieving visible results within the year. </li> </ul> <p> CAMBRIDGE, Mass &amp; RESEARCH TRIANGLE PARK, N.C. &amp; SEOUL, South Korea--(BUSINESS WIRE)-- Hudson Therapeutics announced that Shaperon (KOSDAQ 378800, CEO Seung-Yong Seong), an innovative biopharmaceutical company specializing in immune therapeutics, has signed a Memorandum of Understanding (MOU) with Dong-A ST (KOSPI 170900, CEO Min-Young Kim) for the development of nanobody-based new drugs. </p><p http://www.streetinsider.com/Press+Releases/Shaperon+and+Dong-A+ST+Sign+MOU+for+Nanobody-Based+New+Drug+Development/23342134.html Mon, 10 Jun 2024 15:29:00 -0500 3788 378800 A.26689212 O.10926566 http://www.streetinsider.com/Press+Releases/Shaperon+and+Dong-A+ST+Sign+MOU+for+Nanobody-Based+New+Drug+Development/23342134.html <ul class="bwlistdisc"> <li> Shaperon and Dong-A ST aim to maximize synergy through collaboration between Shaperon's nanobody development platform technology and Dong-A ST's antibody commercialization technology. </li> <li> The joint development of triple nanobody antibodies for cancer treatment is set to accelerate, with the goal of achieving visible results within the year. </li> </ul> <p> CAMBRIDGE, Mass &amp; RESEARCH TRIANGLE PARK, N.C. &amp; SEOUL, South Korea--(BUSINESS WIRE)-- Hudson Therapeutics announced that Shaperon (KOSDAQ 378800, CEO Seung-Yong Seong), an innovative biopharmaceutical company specializing in immune therapeutics, has signed a Memorandum of Understanding (MOU) with Dong-A ST (KOSPI 170900, CEO Min-Young Kim) for the development of nanobody-based new drugs. </p><p http://www.streetinsider.com/Press+Releases/Shaperon+and+Dong-A+ST+Sign+MOU+for+Nanobody-Based+New+Drug+Development/23342134.html Mon, 10 Jun 2024 15:29:00 -0500 3788 378800 A.26689212 O.10926566 http://www.streetinsider.com/Press+Releases/Shaperon+and+Dong-A+ST+Sign+MOU+for+Nanobody-Based+New+Drug+Development/23342134.html <ul class="bwlistdisc"> <li> Shaperon and Dong-A ST aim to maximize synergy through collaboration between Shaperon's nanobody development platform technology and Dong-A ST's antibody commercialization technology. </li> <li> The joint development of triple nanobody antibodies for cancer treatment is set to accelerate, with the goal of achieving visible results within the year. </li> </ul> <p> CAMBRIDGE, Mass &amp; RESEARCH TRIANGLE PARK, N.C. &amp; SEOUL, South Korea--(BUSINESS WIRE)-- Hudson Therapeutics announced that Shaperon (KOSDAQ 378800, CEO Seung-Yong Seong), an innovative biopharmaceutical company specializing in immune therapeutics, has signed a Memorandum of Understanding (MOU) with Dong-A ST (KOSPI 170900, CEO Min-Young Kim) for the development of nanobody-based new drugs. </p><p http://www.streetinsider.com/Press+Releases/Shaperon+and+Dong-A+ST+Sign+MOU+for+Nanobody-Based+New+Drug+Development/23342134.html Mon, 10 Jun 2024 15:29:00 -0500 3788 378800 A.26689212 O.10926566 http://www.streetinsider.com/Business+Wire/Shaperon+and+Dong-A+ST+Sign+MOU+for+Nanobody-Based+New+Drug+Development/23342134.html <ul class="bwlistdisc"> <li> Shaperon and Dong-A ST aim to maximize synergy through collaboration between Shaperon's nanobody development platform technology and Dong-A ST's antibody commercialization technology. </li> <li> The joint development of triple nanobody antibodies for cancer treatment is set to accelerate, with the goal of achieving visible results within the year. </li> </ul> <p> CAMBRIDGE, Mass &amp; RESEARCH TRIANGLE PARK, N.C. &amp; SEOUL, South Korea--(BUSINESS WIRE)-- Hudson Therapeutics announced that Shaperon (KOSDAQ 378800, CEO Seung-Yong Seong), an innovative biopharmaceutical company specializing in immune therapeutics, has signed a Memorandum of Understanding (MOU) with Dong-A ST (KOSPI 170900, CEO Min-Young Kim) for the development of nanobody-based new drugs. </p><p http://www.streetinsider.com/Business+Wire/Shaperon+and+Dong-A+ST+Sign+MOU+for+Nanobody-Based+New+Drug+Development/23342134.html Mon, 10 Jun 2024 15:29:00 -0500 3788 378800 A.26689212 O.10926566 http://www.streetinsider.com/Business+Wire/Shaperon+and+Dong-A+ST+Sign+MOU+for+Nanobody-Based+New+Drug+Development/23342134.html <ul class="bwlistdisc"> <li> Shaperon and Dong-A ST aim to maximize synergy through collaboration between Shaperon's nanobody development platform technology and Dong-A ST's antibody commercialization technology. </li> <li> The joint development of triple nanobody antibodies for cancer treatment is set to accelerate, with the goal of achieving visible results within the year. </li> </ul> <p> CAMBRIDGE, Mass &amp; RESEARCH TRIANGLE PARK, N.C. &amp; SEOUL, South Korea--(BUSINESS WIRE)-- Hudson Therapeutics announced that Shaperon (KOSDAQ 378800, CEO Seung-Yong Seong), an innovative biopharmaceutical company specializing in immune therapeutics, has signed a Memorandum of Understanding (MOU) with Dong-A ST (KOSPI 170900, CEO Min-Young Kim) for the development of nanobody-based new drugs. </p><p http://www.streetinsider.com/Business+Wire/Shaperon+and+Dong-A+ST+Sign+MOU+for+Nanobody-Based+New+Drug+Development/23342134.html Mon, 10 Jun 2024 15:29:00 -0500 3788 378800 A.26689212 O.10926566 http://www.streetinsider.com/Business+Wire/Shaperon+and+Dong-A+ST+Sign+MOU+for+Nanobody-Based+New+Drug+Development/23342134.html <ul class="bwlistdisc"> <li> Shaperon and Dong-A ST aim to maximize synergy through collaboration between Shaperon's nanobody development platform technology and Dong-A ST's antibody commercialization technology. </li> <li> The joint development of triple nanobody antibodies for cancer treatment is set to accelerate, with the goal of achieving visible results within the year. </li> </ul> <p> CAMBRIDGE, Mass &amp; RESEARCH TRIANGLE PARK, N.C. &amp; SEOUL, South Korea--(BUSINESS WIRE)-- Hudson Therapeutics announced that Shaperon (KOSDAQ 378800, CEO Seung-Yong Seong), an innovative biopharmaceutical company specializing in immune therapeutics, has signed a Memorandum of Understanding (MOU) with Dong-A ST (KOSPI 170900, CEO Min-Young Kim) for the development of nanobody-based new drugs. </p><p http://www.streetinsider.com/Business+Wire/Shaperon+and+Dong-A+ST+Sign+MOU+for+Nanobody-Based+New+Drug+Development/23342134.html Mon, 10 Jun 2024 15:29:00 -0500 3788 378800 A.26689212 O.10926566 http://www.streetinsider.com/Business+Wire/Shaperon+and+Dong-A+ST+Sign+MOU+for+Nanobody-Based+New+Drug+Development/23342134.html <ul class="bwlistdisc"> <li> Shaperon and Dong-A ST aim to maximize synergy through collaboration between Shaperon's nanobody development platform technology and Dong-A ST's antibody commercialization technology. </li> <li> The joint development of triple nanobody antibodies for cancer treatment is set to accelerate, with the goal of achieving visible results within the year. </li> </ul> <p> CAMBRIDGE, Mass &amp; RESEARCH TRIANGLE PARK, N.C. &amp; SEOUL, South Korea--(BUSINESS WIRE)-- Hudson Therapeutics announced that Shaperon (KOSDAQ 378800, CEO Seung-Yong Seong), an innovative biopharmaceutical company specializing in immune therapeutics, has signed a Memorandum of Understanding (MOU) with Dong-A ST (KOSPI 170900, CEO Min-Young Kim) for the development of nanobody-based new drugs. </p><p http://www.streetinsider.com/Business+Wire/Shaperon+and+Dong-A+ST+Sign+MOU+for+Nanobody-Based+New+Drug+Development/23342134.html Mon, 10 Jun 2024 15:29:00 -0500 3788 378800 A.26689212 O.10926566